We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Hybrid Liquid Biopsy Platform Enables Tracking and Monitoring of Circulating Tumor Cells

By LabMedica International staff writers
Posted on 01 Apr 2020
Print article
Image: A new fluid analyzing platform allows for the isolation of circulating tumor cells (CTCs), which are formed during metastasis (Photo courtesy of NYU Abu Dhabi)
Image: A new fluid analyzing platform allows for the isolation of circulating tumor cells (CTCs), which are formed during metastasis (Photo courtesy of NYU Abu Dhabi)
By creating a hybrid microfluidic liquid biopsy platform that incorporates atomic force microscopy (AFM), cancer researchers have captured and characterized circulating tumor cells (CTCs), a technique which should prove useful in the diagnosis and prognosis of prostate cancer as well as other forms of cancer.

Circulating tumor cells (CTCs) carried by the patient’s bloodstream are known to lead to the metastatic spread of cancer. Although they are important cancer biomarkers, CTCs are very rare and hard to isolate from the background of billions of healthy blood cells. Nonetheless, it has become clear that an understanding of the nanomechanical characteristics of CTCs, such as elasticity and adhesiveness, would be a significant advancement in tracking and monitoring cancer progression and metastasis.

To attain this understanding, investigators at NYU Dubai (New York, NY, USA and Dubai) developed a combined microfluidic-AFM platform based on specific antibody-based capture of CTCs in whole-blood samples from prostate cancer patients and subsequent characterization of their elasticity and adhesiveness. The microfluidic device was designed to provide a high density of oriented antibodies on its glass surface. The device was assembled via reversible physical polydimethylsiloxane (PDMS)-to-glass bonding, which later allowed external access to captured CTCs. The device was highly efficient in capturing prostate CTCs via antibodies directed at their epithelial cell adhesion molecule (EpCAM), prostate-specific antigen (PSA), and prostate-specific membrane antigen (PSMA).

Atomic force microscopy (AFM) is a type of scanning probe microscopy (SPM), with demonstrated resolution on the order of fractions of a nanometer, more than 1000 times better than the optical diffraction limit. AFM has three major abilities: force measurement, topographic imaging, and manipulation. In force measurement, AFMs can be used to measure the forces between the microscope’s probe and the sample as a function of their mutual separation. This can be applied to measure the mechanical properties of the sample, such as the sample's Young's modulus, a measure of stiffness.

Results revealed that the hybrid biofluidic device was suitable for AFM measurements of captured intact CTCs. When nanomechanically characterized, CTCs originating from metastatic cancer demonstrated decreased elasticity and increased deformability compared to those originating from localized cancer. While the average adhesion of CTCs to the AFM tip surface remained the same in both the groups, there were fewer multiple adhesion events in metastatic CTCs than there were in their counterparts. Thus, the platform was shown to be simple, robust, and reliable and could be useful in the diagnosis and prognosis of prostate cancer as well as other forms of cancer.

"We expect that this platform could constitute a potentially very powerful tool for cancer diagnosis and prognosis, by identifying CTCs mechanical and biological phenotypes at the single cell level," said senior author Dr. Mohammad A. Qasaimeh, assistant professor of mechanical and biomedical engineering at NYU Dubai.

The liquid biopsy-AFM platform was described in the March 23, 2020, online edition of the journal Microsystems and Nanoengineering.

Related Links:
NYU Dubai

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Blood Gas and Chemistry Analysis System
Edan i500
New
Benchtop Cooler
PCR-Cooler & PCR-Rack

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.